» Articles » PMID: 20089263

Laparoscopic Renal Cryoablation: 8-year, Single Surgeon Outcomes

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 2010 Jan 22
PMID 20089263
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We present 5 to 11-year (median 8) oncological outcomes after laparoscopic renal cryoablation.

Materials And Methods: Between September 1997 and October 2008 we performed renal cryoablation in 340 patients, of whom 80 treated laparoscopically by a single surgeon before October 2003 had a minimum 5-year followup. Followup involved magnetic resonance imaging on postoperative day 1, at 3, 6 and 12 months, and annually thereafter. Cryolesion biopsy was performed at 6 months. All data were prospectively accrued.

Results: In the 80 patients with minimum 5-year followup mean age was 66 years, mean tumor size was 2.3 cm (range 0.9 to 5.0), median American Society of Anesthesiologists score was 3 and mean body mass index was 28 kg/m(2). Five patients had local recurrence, 2 had locoregional recurrence with metastasis and 4 had distant metastasis without locoregional recurrence. Six patients died of cancer. In the 55 patients with biopsy proven renal cell cancer at a median followup of 93 months (range 60 to 132) 5-year overall, disease specific and disease-free survival rates were 84%, 92% and 81%, and 10-year rates were 51%, 83% and 78%, respectively. On multivariate analysis previous radical nephrectomy for RCC was the only significant predictor of disease-free and disease specific survival (p = 0.023 and 0.030, respectively).

Conclusions: Laparoscopic renal cryoablation is effective oncological treatment for a renal mass in select patients. A disease specific survival rate of 92% at 5 years and 83% at 10 years is possible. Preceding radical nephrectomy for renal cell carcinoma was the only independent factor predicting disease-free and disease specific survival.

Citing Articles

The Role of Focal Therapy and Active Surveillance for Small Renal Mass Therapy.

Matuszczak M, Kiljanczyk A, Salagierski M Biomedicines. 2022; 10(10).

PMID: 36289844 PMC: 9599744. DOI: 10.3390/biomedicines10102583.


Laparoscopic cryoablation for small renal masses: Oncological outcomes at 5-year follow-up.

M E L Henderickx M, Strater-Ruiter A, van der West A, Beerlage H, Zondervan P, Lagerveld B Arab J Urol. 2021; 19(2):159-165.

PMID: 34104491 PMC: 8158258. DOI: 10.1080/2090598X.2020.1863308.


Treatment options for localised renal cell carcinoma of the transplanted kidney.

Motta G, Ferraresso M, Lamperti L, Paolo D, Raison N, Perego M World J Transplant. 2020; 10(6):147-161.

PMID: 32742948 PMC: 7360528. DOI: 10.5500/wjt.v10.i6.147.


Focal therapy versus robot-assisted partial nephrectomy in the management of clinical T1 renal masses: A systematic review and meta-analysis.

Yoon Y, Lee H, Kim K, Park S, Moon H, Lee S Medicine (Baltimore). 2018; 97(45):e13102.

PMID: 30407321 PMC: 6250551. DOI: 10.1097/MD.0000000000013102.


Demographic characteristics and complications of open and minimally invasive surgeries for renal cell carcinoma: a population-based case-control study in Taiwan.

Chang Y, Chang S, Liu C, Lin P, Yu K, Pang S Ther Clin Risk Manag. 2018; 14:1235-1241.

PMID: 30038497 PMC: 6049605. DOI: 10.2147/TCRM.S164592.